HOOKIPA Pharma Inc
NASDAQ:HOOK
Net Margin
HOOKIPA Pharma Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
HOOKIPA Pharma Inc
NASDAQ:HOOK
|
10m USD |
-784%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
364.7B USD |
6%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
157.9B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
146.8B USD |
22%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
100.1B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
131.4B AUD |
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.4B USD |
31%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
59.7B USD |
-13%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
HOOKIPA Pharma Inc
Glance View
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2019-04-18. The firm is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its pipeline candidates include HB-200, HB-300, HB-700, HB-101, HB-101 and HBV Therapy. The HB-200 program consists of its arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by 16-positive (HPV16+). Its lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus HPV16+ cancers in a Phase I/II clinical trial. Its non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is for patients awaiting kidney transplantation in Phase II clinical trial.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on HOOKIPA Pharma Inc's most recent financial statements, the company has Net Margin of -784%.
You don't have any saved screeners yet